title: Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression.
abstract: Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when compared with non-platinum-based regimens in TNBC and non-TNBC. A retrospective analysis was conducted within a cohort of patients with metastatic breast cancer who received platinum-based chemotherapy at a single institution. Data were collected for up to three lines of treatment for metastatic disease. Time to progression was determined for platinum-based chemotherapy and non-platinum-based regimens for each line of treatment. Adjusted hazard ratios (HRs), together with 95% confidence intervals (CIs) were estimated comparing the time to progression associated with the use of platinum-based chemotherapy versus non-platinum-based regimens. A total of 159 patients were included in the analysis, with 58 diagnosed with TNBC. Among the patients with TNBC, compared with non-platinum-based chemotherapy, no correlation was identified between platinum-based chemotherapy and an improved time to progression [first line: HR, 0.97 (95% CI, 0.40-2.35); second line: HR, 0.91 (95% CI, 0.42-2.01); and third line: HR, 2.83 (95% CI, 0.73-11.03)]. By contrast, patients with non-TNBC appeared to improve with non-platinum-based chemotherapy [first line: HR, 2.57 (95% CI, 1.11-5.99); second line: HR, 1.91 (95% CI, 1.00-3.63); and third line: HR, 1.08 (95% CI, 0.53-2.18)]. Although the present study was limited by the sample size and its observational nature, the results indicated that platinum-based chemotherapy does not offer a discernible or distinct advantage compared with standard regimens in patients with TNBC, and is perhaps less efficacious in patients with non-TNBC.
authors: Division of Hematology-Oncology, University of Montreal - Notre-Dame Hospital, Montreal, QC H2L 4M1, Canada ; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
authors: Daniel
authors: D
authors: Khalaf
authors: Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
authors: John F
authors: JF
authors: Hilton
authors: Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
authors: Mark
authors: M
authors: Clemons
authors: Department of Oncology, Royal Victoria Hospital, McGill University, Montreal, QC H3A 1A1, Canada ; Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
authors: Laurent
authors: L
authors: Azoulay
authors: Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
authors: Hui
authors: H
authors: Yin
authors: Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
authors: Lisa
authors: L
authors: Vandermeer
authors: Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
authors: Susan
authors: S
authors: Dent
authors: Department of Pharmacy, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
authors: Sean
authors: S
authors: Hopkins
authors: Department of Oncology, Royal Victoria Hospital, McGill University, Montreal, QC H3A 1A1, Canada.
authors: Nathaniel
authors: N
authors: Bouganim
keywords: metastatic breast cancer; platinum; time to progression; triple-negative breast cancer